Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Learn which Index Funds To Include In Portfolio to create a diversified, low-cost core. Use this guide to shape a resilient allocation strategy.
25,828 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Analysts issued fresh upgrades on a slate of big-name stocks as earnings season continues. Applied Materials, Devon E...
Onsemi posted weaker Q1 2026 results amid a slowing silicon carbide market and rising competition from Sony in image ...
A midlife couple faces a classic dilemma after selling a home: extinguish debt at 5% or invest the $175,000 cash pile...
The trillion-dollar club is expanding, and a few ahead-of-the-curve signals can help you spot the next member. This g...
Astera Labs’ stock jumped after management laid out a firm timetable for a new switch and signaled growing opportunit...
A synthetic covered‑call ETF on MicroStrategy stock continues to pay outs through monthly distributions, yet the stra...
If SpaceX ever files for an IPO, the prospectus would reveal the core drivers, the risks, and the questions investors...
As tensions flare, shipping traffic through Hormuz is increasingly split between a U.S.-led lane and Iran’s control, ...
The AI build-out isn’t slowing Nvidia, with hyperscalers accelerating capex and expanding the AI stack. Investors are...
The AI race is heating up, and anthropic (claude) only trillion is a headline that won’t fade. This article breaks do...
A small group of everyday investors rode space-data trends to multimillion-dollar gains years before a SpaceX IPO hea...